Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr.
Microvention, Inc. · Decision date May 30, 2018
What did the FDA approve?
FDA approved PMA P170013 for the Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. from MicroVention, Inc. The approval statement describes the device as indicated for use with neurovascular embolization coils in patients 18 years or older for wide-neck saccular intracranial aneurysms, defined as neck width of 4 mm or greater or dome-to-neck ratio below 2, arising from a parent vessel with diameter between 2.0 mm and 4.5 mm.
The decision date is May 30, 2018, and the product code is QCA under the specialty of Neurology. The record does not include a supplement type or supplement reason, so no changed item or relationship to an earlier PMA is stated. The approval statement reports the device's indicated use but does not itself provide independent proof of safety or clinical effectiveness.
FDA approval order statement
Approval for the Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. This device is indicated for use with neurovascular embolization coils in patients >= 18 years of age for the treatment of wide-neck (neck width >= 4 mm or dome to neck ratio < 2) saccular intracranial aneurysms arising from a parent vessel with a diameter >= 2.0 mm and <= 4.5 mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- May 30, 2018
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170013
- Regulatory pathway
- Premarket approval application
- Applicant
- Microvention, Inc.
- Product code
- QCA
- Decision code
- APPR
- Decision date
- May 30, 2018
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial coil-assist stent.
- Applicant
- Microvention, Inc.
- Product code
- QCA
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170013 received
Application receipt date recorded by FDA.
P170013 · FDA decision
APPR
P170013/S013 · Related supplement
Intraluminal Support Device LVIS/LVIS Jr./LVIS EVO
Timeline entries are records held by MedtechLedger for P170013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code QCA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuroform Atlas Stent SystemP180031/S012 | Stryker Neurovascular | PMA supplement | Oct 24, 2026 | FDA |
Neuroform Atlas Stent SystemP180031 | Stryker Neurovascular | PMA approval | May 16, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microvention, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 35 Enterprise, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P170013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
